On December 31, 2025, The Supreme People's Court upheld the Beijing IP Court's decision, meaning that the semaglutide patent remains valid and will expire on March 20, 2026.

Starting in 2023, Datang Mobile, one of the key players in China's telecom standardization efforts, initiated infringement proceedings against Samsung in China, Germany, and the US.

Crystalline forms are critical to pharmaceutical patents, offering extended protection for improved stability, bioavailability, or manufacturability. However, securing such patents in China has grown increasingly difficult due to the China National Intellectual Property Administration (CNIPA)'s strict patentability criteria.

Foreign companies targeting the Asian market often misunderstand Hong Kong's unique intellectual property framework, leading to costly protection gaps.

Each year the CNIPA publishes its Top Ten Patent Re-examination and Invalidation Cases for the previous year.

As AI models become versatile and adaptable across multiple contexts and industries, questions about inventive step sit at the heart of patent examination in China...

China's Supreme People's Court has issued its first public decision clarifying the country's inventorship standards, revealing significant differences from U.S. patent law...

RNAi is a fast-developing technology that has gained traction in the pharmaceutical industry as a promising therapeutic agent.

The rapid growth of AI patent applications present significant challenges to existing patent application and examination practices.

A Chinese robot vacuum company digs up "hidden evidence" to successfully invalidate a patent owned by its biggest competitor.

In China, innovative drug companies typically rely on their initial composition of matter patents to block out competitors.

In patent prosecution, the concept of a "conflicting application" or "secret prior art" plays a critical role in determining the patentability of an invention.

"Good Faith" is a challenging concept that brings with it the nuances of a particular jurisdiction's ideas about honesty, moral values, and societal expectations.

Each year the CNIPA releases a list of Top Ten Patent Re-examination and Invalidation Cases. These cases are meant to be guiding cases...

"Parameter features" – numerical or mathematical expressions that define the quantity or physical properties of a subject – frequently appear as technical features within a claim.

The high-profile disputes surrounding an important CRISPR patent belonging to The Broad Institute, MIT and Harvard (hereinafter "the proprietors") has attracted a lot of attention in recent years, particularly regarding the validity of priority rights that were challenged worldwide.

A recent CNIPA invalidation case examines how precision medicine patents are evaluated in China, specifically addressing whether patient stratification based on biomarkers like serum alkaline phosphatase levels constitutes valid claim limitations. The decision provides critical guidance on what evidence is required to establish new patient subgroups and how disease markers must demonstrate clinical guidance value to support inventive step arguments.

Precision medicine is rapidly transforming the global healthcare landscape, providing more effective therapies and better patient outcomes through targeted solutions.

China's Supreme People's Court has established a groundbreaking precedent in pharmaceutical patent law, ruling that therapeutic effects comparable to drugs approved after a patent's filing date...

China's Supreme People's Court has issued a landmark ruling that fundamentally reshapes how patent inventiveness is assessed, moving away from subjective hindsight bias...